318
Views
62
CrossRef citations to date
0
Altmetric
Articles

Design and development of novel focal adhesion kinase (FAK) inhibitors using Monte Carlo method with index of ideality of correlation to validate QSAR

ORCID Icon, &
Pages 63-80 | Received 18 Oct 2018, Accepted 24 Dec 2018, Published online: 22 Feb 2019

References

  • R.O. Hynes, Integrins: Bidirectional, allosteric signaling machines, Cell 110 (2002), pp. 673–687.
  • M. Larsen, V.V. Artym, J.A. Green, and K.M. Yamada, The matrix reorganized: Extracellular matrix remodeling and integrin signaling, Curr. Opin. Cell Biol. 18 (2006), pp. 463–471.
  • W. Guo and F.G. Giancotti, Integrin signalling during tumour progression, Nat. Rev. Mol. Cell Biol. 5 (2004), pp. 816–826.
  • P.J. Reddig and R.L. Juliano, Clinging to life: Cell to matrix adhesion and cell survival, Cancer Metastasis Rev. 24 (2005), pp. 425–439.
  • S.T. Lim, D. Mikolon, D.G. Stupack, and D.D. Schlaepfer, FERM control of FAK function: Implications for cancer therapy, Cell Cycle 7 (2008), pp. 2306–2314.
  • M.A. Cabrita, L.M. Jones, J.L. Quizi, L.A. Sabourin, B.C. McKay, and C.L. Addison, Focal adhesion kinase inhibitors are potent anti-angiogenic agents, Mol. Onco. 5 (2011), pp. 517–526.
  • P. Dao, D. Lietha, M. Etheve-Quelquejeu, C. Garbay, and H. Chen, Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity, Bio. Med. Chem. Lett. 27 (2017), pp. 1727–1730.
  • N.E. Uko, O.F. Güner, L.M.A. Barnett, D.F. Matesic, and J.P. Bowen, Discovery and biological activity of computer-assisted drug designed Akt pathway inhibitors, Bio. Med. Chem. Lett. 28 (2018), pp. 3247–3250.
  • J.F. Ellenbarger, I.V. Krieger, H.-L. Huang, S. Gómez-Coca, T.R. Ioerger, J.C. Sacchettini, S.E. Wheeler, and K.R. Dunbar, Anion-π interactions in computer-aided drug design: Modeling the inhibition of malate synthase by phenyl-diketo acids, J. Chem. Inf. Mod. (2018), pp. 2085–2091.
  • A. Daina, M.-C. Blatter, V. Baillie Gerritsen, P.M. Palagi, D. Marek, I. Xenarios, T. Schwede, O. Michielin, and V. Zoete, Drug design workshop: A web-based educational tool to introduce computer-aided drug design to the general public, J. Chem. Edu. 94 (2017), pp. 335–344.
  • A. Abdolmaleki, J.B. Ghasemi, and F. Ghasemi, Computer aided drug design for multi-target drug design: SAR/QSAR, molecular docking and pharmacophore methods, Curr. Drug Target. 18 (2017), pp. 556–575.
  • H. Gao, J.A. Katzenellenbogen, R. Garg, and C. Hansch, Comparative QSAR analysis of estrogen receptor ligands, Chem. Rev. 99 (1999), pp. 723–744.
  • D. Hadjipavlou-Litina, R. Garg, and C. Hansch, Comparative quantitative structure–activity relationship studies (QSAR) on non-benzodiazepine compounds binding to benzodiazepine receptor (BzR), Chem. Rev. 104 (2004), pp. 3751–3794.
  • C. Hansch, D. Hoekman, and H. Gao, Comparative QSAR: Toward a deeper understanding of chemicobiological interactions, Chem. Rev. 96 (1996), pp. 1045–1076.
  • S. Thareja, Steroidal 5-alpha-reductase inhibitors: A comparative 3D-QSAR study review, Chem. Rev. 115 (2015), pp. 2883–2894.
  • S. Agatonovic-Kustrin, D.W. Morton, and D. Celebic, QSAR: An in silico approach for predicting the partitioning of pesticides into breast milk, Comb. Chem. High Thro. Scr. 16 (2013), pp. 223–232.
  • A. Aouidate, A. Ghaleb, M. Ghamali, A. Ousaa, M. Choukrad, A. Sbai, M. Bouachrine, and T. Lakhlifi, 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase, Comput. Biol. Chem. 74 (2018), pp. 201–211.
  • V. Stoickov, D. Stojanovic, I. Tasic, S. Saric, D. Radenkovic, P. Babovic, D. Sokolovic, and A.M. Veselinovic, QSAR study of 2,4-dihydro-3H-1,2,4-triazol-3-ones derivatives as angiotensin II AT(1) receptor antagonists based on the Monte Carlo method, Struct. Chem. 29 (2018), pp. 441–449.
  • A. Kumar and S. Chauhan, QSAR differential model for prediction of SIRT1 modulation using Monte Carlo method, Drug Res. 67 (2017), pp. 156–162.
  • A. Kumar and S. Chauhan, Monte Carlo method based QSAR modelling of natural lipase inhibitors using hybrid optimal descriptors, SAR QSAR Environ. Res. 28 (2017), pp. 179–197.
  • A. Kumar and S. Chauhan, Use of the Monte Carlo method for OECD principles-guided QSAR modeling of SIRT1 inhibitors, Arch Pharm. 350 (2017), doi: 10.1002/ardp.201600268 [ Epub ahead of print].
  • A.P. Toropova, A.A. Toropov, A.M. Veselinovic, J.B. Veselinovic, D. Leszczynska, and J. Leszczynski, Monte Carlo-based quantitative structure–activity relationship models for toxicity of organic chemicals to Daphnia magna, Environ. Toxicol. Chem. 35 (2016), pp. 2691–2697.
  • P. Kumar and A. Kumar, Monte Carlo method based QSAR studies of mer kinase inhibitors in compliance with OECD principles, Drug Res. (Stuttg). 68 (2018), pp. 189–195.
  • P. Kumar, R. Bhatia, R. Khanna, A. Dalal, D. Kumar, P. Surain, and R.C. Kamboj, Synthesis of some benzothiazoles by developing a new protocol using urea nitrate as a catalyst and their antimicrobial activities, J. Sul. Chem. 38 (2017), pp. 585–596.
  • P. Kumar, M. Duhan, K. Kadyan, J. Sindhu, S. Kumar, and H. Sharma, Synthesis of novel inhibitors of α-amylase based on thiazolidine-4-one skeleton containing pyrazole moiety and their configurational studies, Med. Chem. Comm. 8 (2017), pp. 1468–1476.
  • R. Kumar, R. Khanna, P. Kumar, V. Kumar, and R.C. Kamboj, Synthesis of some 4‐quinolinyl pyridines and their antimicrobial and docking studies, J. Het. Chem. 54 (2017), pp. 2740–2747.
  • P. Kumar, M. Duhan, K. Kadyan, J.K. Bhardwaj, P. Saraf, and M. Mittal, Multicomponent synthesis of some molecular hybrid containing thiazole pyrazole as apoptosis inducer, Drug Res. (Stuttg). 68 (2018), pp. 72–79.
  • P. Cheng, J. Li, J. Wang, X. Zhang, and H. Zhai, Investigations of FAK inhibitors: A combination of 3D-QSAR, docking, and molecular dynamics simulations studies, J. Biol. Struct. Dyn. 36 (2018), pp. 1529–1549.
  • P. Dao, R. Jarray, J. Le Coq, D. Lietha, A. Loukaci, Y. Lepelletier, R. Hadj-Slimane, C. Garbay, F. Raynaud, and H. Chen, Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity, Bio. Med. Chem. Lett. 23 (2013), pp. 4552–4556.
  • P. Dao, N. Smith, C. Tomkiewicz-Raulet, E. Yen-Pon, M. Camacho-Artacho, D. Lietha, J.-P. Herbeuval, X. Coumoul, C. Garbay, and H. Chen, Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity, J. Med. Chem. 58 (2015), pp. 237–251.
  • N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3:33(2011), pp. 1–14. doi:10.1186/1758-2946-3-33
  • A.A. Toropov, A.P. Toropova, E. Benfenati, G. Gini, and R. Fanelli, The definition of the molecular structure for potential anti-malaria agents by the Monte Carlo method, Struct. Chem. 24 (2013), pp. 1369–1381.
  • P. Kumar, A. Kumar, J. Sindhu, and S. Lal, QSAR models for nitrogen containing monophosphonate and bisphosphonate derivatives as human farnesyl pyrophosphate synthase inhibitors based on Monte Carlo method, Drug Res. (Stuttg). (2018) doi: 10.1055/a-0652-5290 [ Epub ahead of print] .
  • A.P. Toropova and A.A. Toropov, The index of ideality of correlation: A criterion of predictability of QSAR models for skin permeability?, Sci. Total Environ. 586 (2017), pp. 466–472.
  • A.A. Toropov and A.P. Toropova, The index of ideality of correlation: A criterion of predictive potential of QSPR/QSAR models?, Mutat. Res. 819 (2017), pp. 31–37.
  • A.P. Toropova and A.A. Toropov, CORAL: Monte Carlo method to predict endpoints for medical chemistry, Mini Rev. Med. Chem. 18 (2018), pp. 382–391.
  • A.A. Toropov, R. Carbó-Dorca, and A.P. Toropova, Index of ideality of correlation: New possibilities to validate QSAR: A case study, Struct. Chem. 29 (2018), pp. 33–38.
  • K. Roy, On some aspects of validation of predictive quantitative structure–activity relationship models, Expert Opin. Drug Discov. 2 (2007), pp. 1567–1577.
  • P.P. Roy, J.T. Leonard, and K. Roy, Exploring the impact of size of training sets for the development of predictive QSAR models, Chemom. Intell. Lab. Syst. 90 (2008), pp. 31–42.
  • A. Golbraikh and A. Tropsha, Beware of q2!, J Mol Graph Model. 20 (2002), pp. 269–276.
  • P.K. Ojha and K. Roy, Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection, Chemom. Intell. Lab. Syst. 109 (2011), pp. 146–161.
  • OECD, Guidance document on the validation of (quantitative) structure–activity relationship [(Q)SAR] models, OECD Series on Testing and Assessment, No. 69, (2014) OECD Publishing, Paris, https://doi.org/10.1787/9789264085442-en.
  • A.M. Veselinovic, A. Toropov, A. Toropova, D.S. Dordevic, and J.B. Veselinovic, Design and development of novel antibiotics based on FtsZ inhibition – In silico studies, New J. Chem.42 (2018), pp. 10976–10982.
  • O. Trott and A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461.
  • A. Pedretti, L. Villa, and G. Vistoli, VEGA: A versatile program to convert, handle and visualize molecularstructure on WINDOWS-based PCs, J. Mol. Graph. 21 (2002), pp. 47–49.
  • P. Dao, R. Jarray, N. Smith, Y. Lepelletier, J. Le Coq, D. Lietha, R. Hadj-Slimane, J. Herbeuval, C. Garbay, F. Raynaud, and H. Chen, Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities, Cancer Lett. 348 (2014), pp. 88–99.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.